- Home
- PLUR vs BOLD Comparison
PLUR vs BOLD Comparison
Compare PLUR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUR | BOLD |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 28.4M |
| IPO Year | 2001 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PLUR | BOLD |
|---|---|---|
| Price | $3.67 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $12.00 | $4.00 |
| AVG Volume (30 Days) | 11.7K | ★ 149.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.78 | ★ 90.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,336,000.00 | N/A |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $0.96 |
| 52 Week High | $7.13 | $2.05 |
Technical Indicators
Market Signals| Indicator | PLUR | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 48.10 |
| Support Level | $3.43 | $1.12 |
| Resistance Level | $3.85 | $1.19 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 68.92 | 81.16 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.